Baseline characteristics of patients with very high risk
of ASCVD
A total of 453 patients treated with PCSK-9 inhibitors combined with
statin and 2,610 patients treated with statins were recruited in the
cohort. Among all patients, 89.91% had received moderate or
high-intensity statin therapy before PCI (eFigure 1A), but only 9.47%
of them had LDL levels below 1.4mmol/L (eFigure 1B). The proportion of
patients with Lp(a) level >430mmol/L was 44.85%.
PSM selected a subgroup of 868 patients (434 initiated treated with
PCSK-9 and 434 treated with statins) were used for comparative
effectiveness analysis in current study. The follow-up rate of 868
patients was 100% at 6 months. The patient flow chart was showed in
eFigure 2.
The baseline characteristics of matched patients were summarized in
Table 1. There was no statistical significant difference in age, gender,
BMI, comorbidities, smoker and medical treatment after matched, but
incidence of past history of MI, PCI, CABG, STEMI and ischemic
cardiomyopathy in PSCK-9 inhibitor group is higher (all withP <0.001).